e-Therapeutics - Keeping the faith
e-Therapeutics’ (ETX) H118 results were a routine financial update highlighting its continuing focus on partnering the Network-driven Drug...
51 Views
e-Therapeutics - A matter of time until prime time
With the refocusing of the business and the new CEO’s strategic review now implemented, e-Therapeutics (ETX) finds itself with the NDD platform and...
68 Views
e-Therapeutics - Nearing prime time validation
e-Therapeutics’ (ETX) Network-Driven Drug Discovery (NDD) platform has begun to deliver encouraging data that should support out-licensing of its...
66 Views
Sailing a steady course
e-Therapeutics’ (ETX) interim numbers demonstrate tight cost control and focus on the rationalised pipeline, with continued investment into the...
67 Views
Strategic review complete: focus on deal-making
New CEO Dr Ray Barlow, who joined e-Therapeutics (ETX) in April, has undertaken a business and strategic review, assisted by an independent...
91 Views